Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 2
2000 1
2003 2
2004 2
2005 14
2006 18
2007 32
2008 63
2009 85
2010 131
2011 195
2012 227
2013 270
2014 315
2015 338
2016 386
2017 416
2018 451
2019 425
2020 1335
2021 1451
2022 1049
2023 96
Text availability
Article attribute
Article type
Publication date

Search Results

6,249 results
Results by year
Filters applied: . Clear all
Page 1
Tocilizumab (Actemra).
Sheppard M, Laskou F, Stapleton PP, Hadavi S, Dasgupta B. Sheppard M, et al. Hum Vaccin Immunother. 2017 Sep 2;13(9):1972-1988. doi: 10.1080/21645515.2017.1316909. Hum Vaccin Immunother. 2017. PMID: 28841363 Free PMC article. Review.
Tocilizumab (TCZ), is a recombinant humanized anti-interleukin-6 receptor (IL-6R) monoclonal antibody which has a main use in the treatment of rheumatoid arthritis, systemic juvenile idiopathic arthritis (sJIA) and polyarticular juvenile idiopathic arthritis (pJIA). This a
Tocilizumab (TCZ), is a recombinant humanized anti-interleukin-6 receptor (IL-6R) monoclonal antibody which has a main use in the tre
Tocilizumab (Actemra®).
[No authors listed] [No authors listed] 2021 Oct. Mother To Baby | Fact Sheets [Internet]. Brentwood (TN): Organization of Teratology Information Specialists (OTIS); 1994–. 2021 Oct. Mother To Baby | Fact Sheets [Internet]. Brentwood (TN): Organization of Teratology Information Specialists (OTIS); 1994–. PMID: 35952254 Free Books & Documents. Review.
Esta hoja trata de la exposicion a tocilizumab en el embarazo y durante la lactancia. Esta informacion no debe usarse como un sustituto de la atencion medica o los consejos de su proveedor de atencion de salud....
Esta hoja trata de la exposicion a tocilizumab en el embarazo y durante la lactancia. Esta informacion no debe usarse como un sustitu …
Tocilizumab (Actemra®).
[No authors listed] [No authors listed] 2021 Oct 1. Mother To Baby | Fact Sheets [Internet]. Brentwood (TN): Organization of Teratology Information Specialists (OTIS); 1994–. 2021 Oct 1. Mother To Baby | Fact Sheets [Internet]. Brentwood (TN): Organization of Teratology Information Specialists (OTIS); 1994–. PMID: 35952253 Free Books & Documents. Review.
This sheet is about exposure to tocilizumab in pregnancy and while breastfeeding. This information should not take the place of medical care and advice from your healthcare provider....
This sheet is about exposure to tocilizumab in pregnancy and while breastfeeding. This information should not take the place of medic …
An EUA for tocilizumab (Actemra) for COVID-19.
[No authors listed] [No authors listed] Med Lett Drugs Ther. 2021 Jul 26;63(1629):113-114. Med Lett Drugs Ther. 2021. PMID: 34544106 Review. No abstract available.
Trial of Tocilizumab in Giant-Cell Arteritis.
Stone JH, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D, Brouwer E, Cid MC, Dasgupta B, Rech J, Salvarani C, Schett G, Schulze-Koops H, Spiera R, Unizony SH, Collinson N. Stone JH, et al. N Engl J Med. 2017 Jul 27;377(4):317-328. doi: 10.1056/NEJMoa1613849. N Engl J Med. 2017. PMID: 28745999 Free article. Clinical Trial.
The key secondary outcome was the rate of remission in each tocilizumab group as compared with the placebo group that underwent the 52-week prednisone taper. ...Serious adverse events occurred in 15% of the patients in the group that received tocilizumab weekly, 14% …
The key secondary outcome was the rate of remission in each tocilizumab group as compared with the placebo group that underwent the 5 …
Tocilizumab: A Review in Rheumatoid Arthritis.
Scott LJ. Scott LJ. Drugs. 2017 Nov;77(17):1865-1879. doi: 10.1007/s40265-017-0829-7. Drugs. 2017. PMID: 29094311 Free PMC article. Review.
In the clinical trial and real-world settings, tocilizumab monotherapy or combination therapy provided rapid and sustained improvements in clinical and radiographic outcomes and health-related quality of life. The safety profile of tocilizumab is consistent over tim …
In the clinical trial and real-world settings, tocilizumab monotherapy or combination therapy provided rapid and sustained improvemen …
Tocilizumab: the first interleukin-6-receptor inhibitor.
Sebba A. Sebba A. Am J Health Syst Pharm. 2008 Aug 1;65(15):1413-8. doi: 10.2146/ajhp070449. Am J Health Syst Pharm. 2008. PMID: 18653811 Review.
In general, tocilizumab as monotherapy and in combination with methotrexate appears to be well tolerated. ...A large clinical trial is needed to confirm tocilizumab's clinical efficacy and safety....
In general, tocilizumab as monotherapy and in combination with methotrexate appears to be well tolerated. ...A large clinical trial i …
Tocilizumab (Actemra): Adult Patients with Moderately to Severely Active Rheumatoid Arthritis [Internet].
[No authors listed] [No authors listed] Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2015 Aug. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2015 Aug. PMID: 26962613 Free Books & Documents. Review.
Based on Canadian Rheumatology Association guidelines, if patients do not attain the desired target within three to six months of non-biologic DMARD therapy, treatment with a biologic therapy should be initiated. Tocilizumab (TCZ) is a recombinant humanized anti-human inte …
Based on Canadian Rheumatology Association guidelines, if patients do not attain the desired target within three to six months of non-biolog …
Tocilizumab (Actemra, Intravenous): For the Treatment of Signs and Symptoms of Active Polyarticular Juvenile Idiopathic Arthritis in Patients Two Years of Age and Older Who Have Responded Inadequately to Previous Therapy With Disease-Modifying Antirheumatic Drugs and Systemic Corticosteroids [Internet].
[No authors listed] [No authors listed] Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2014 Aug. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2014 Aug. PMID: 25411665 Free Books & Documents. Review.
The objective of this systematic review is to examine the beneficial and harmful effects of IV tocilizumab in the treatment of active polyarticular juvenile idiopathic arthritis (pJIA)....
The objective of this systematic review is to examine the beneficial and harmful effects of IV tocilizumab in the treatment of active …
[COVID-19: Still a place for tocilizumab?].
Richier Q, Plaçais L, Lacombe K, Hermine O. Richier Q, et al. Rev Med Interne. 2021 Feb;42(2):73-78. doi: 10.1016/j.revmed.2020.11.016. Epub 2020 Nov 27. Rev Med Interne. 2021. PMID: 33288230 Free PMC article. Review. French. No abstract available.
6,249 results